MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma

Oncogene

Volumn 30, Issue 40, 2011, Pages 4152-4162

  Zhai, Y ^a   Iura, A ^a   Yeasmin, S ^a   Wiese, A B ^a   Wu, R ^a   Feng, Y ^a   Fearon, E R ^a   Cho, K R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

b catenin; endometrioid; MSX2; ovarian cancer; WNT signaling

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; K RAS PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR MSX2; WNT PROTEIN; WNT3A PROTEIN;

ARTICLE; BINDING KINETICS; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; ONCOGENE; OVARIAN ENDOMETRIOID ADENOCARCINOMA; OVARY ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

MURINAE; RODENTIA;

EID: 85027953706     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.123     Document Type: Article

References (38)

1. Bendall AJ, Abate-Shen C. (2000). Roles for Msx and Dlx homeoproteins in vertebrate development. Gene 247: 17-31. (Pubitemid 30201557)
2. Bommer GT, Feng Y, Iura A, Giordano TJ, Kuick R, Kadikoy H et al. (2010). IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem 285: 1928-1938.
3. Catasus L, Bussaglia E, Rodrguez I, Gallardo A, Pons C, Irving JA et al. (2004). Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35: 1360-1368. (Pubitemid 39601576)
4. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE. (2005). FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 24: 73-84. (Pubitemid 40188465)
5. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. (2005). Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11: 531-537. (Pubitemid 40685976)
6. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ et al. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793-803.
7. di Bari MG, Ginsburg E, Plant J, Strizzi L, Salomon DS, Vonderhaar BK. (2009). Msx2 induces epithelial-mesenchymal transition in mouse mammary epithelial cells through upregulation of Cripto-1. J Cell Physiol 219: 659-666.
8. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. (2005). Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11: 63-70. (Pubitemid 40215839)
9. Dodig M, Tadic T, Kronenberg MS, Dacic S, Liu YH, Maxson R et al. (1999). Ectopic Msx2 overexpression inhibits and Msx2 anti-sense stimulates calvarial osteoblast differentiation. Dev Biol 209: 298-307. (Pubitemid 29230881)
10. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. (1999). beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene Mutations, Clin-icopathological features, and clinical outcome. Amer J Path 155: 527-536. (Pubitemid 29370402)
11. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. (2006). Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66: 1354-1362. (Pubitemid 43259914)
12. Hussein SM, Duff EK, Sirard C. (2003). Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. J Biol Chem 278: 48805-48814. (Pubitemid 41079523)
13. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. (2002). Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22: 1172-1183. (Pubitemid 34094853)
14. Jiang TX, Liu YH, Widelitz RB, Kundu RK, Maxson RE, Chuong CM. (1999). Epidermal dysplasia and abnormal hair follicles in transgenic mice overexpressing homeobox gene MSX-2. J Invest Dermatol 113: 230-237. (Pubitemid 30202528)
15. Kolligs FT, Hu G, Dang CV, Fearon ER. (1999). Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 19: 5696-5706. (Pubitemid 29339926)
16. Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y et al. (2002). ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 1: 145-155.
17. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL et al. (2009). Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601.
18. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S et al. (2002). Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 277: 21657-21665. (Pubitemid 34952316)
19. Parker DS, Ni YY, Chang JL, Li J, Cadigan KM. (2008). Wingless signaling induces widespread chromatin remodeling of target loci. Mol Cell Biol 28: 1815-1828.
20. Ramos C, Robert B. (2005). msh/Msx gene family in neural development. Trends Genet 21: 624-632. (Pubitemid 41429291)
21. Sagae S, Kobayashi K, Nishioka Y, Sugimura M, Ishioka S, Nagata M et al. (1999). Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res 90: 510-515. (Pubitemid 29267704)
22. Satoh K, Ginsburg E, Vonderhaar BK. (2004). Msx-1 and Msx-2 in mammary gland development. J Mammary Gland Biol Neoplasia 9: 195-205. (Pubitemid 39177503)
23. Satoh K, Hamada S, Kimura K, Kanno A, Hirota M, Umino J et al. (2008). Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol 172: 926-939. (Pubitemid 351519990)
24. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K et al. (2000). Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 24: 391-395. (Pubitemid 30187439)
25. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM et al. (2002). Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729.
26. Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA et al. (2003). Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63: 2913-2922. (Pubitemid 36667164)
27. Shah N, Sukumar S. (2010). The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10: 361-371.
28. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. (2005). Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115: 1210-1220. (Pubitemid 40629039)
29. Song L, Li Y, Wang K, Wang YZ, Molotkov A, Gao L et al. (2009). Lrp6-mediated canonical Wnt signaling is required for lip formation and fusion. Development 136: 3161-3171.
30. Suzuki M, Tanaka M, Iwase T, Naito Y, Sugimura H, Kino I. (1993). Over-expression of HOX-8, the human homologue of the mouse Hox-8 homeobox gene, in human tumors. Biochem Biophys Res Commun 194: 187-193. (Pubitemid 23237918)
31. Takahashi C, Akiyama N, Matsuzaki T, Takai S, Kitayama H, Noda M. (1996). Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene. Oncogene 12: 2137-2146. (Pubitemid 26168423)
32. Whyte DB, Holbeck SL. (2006). Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 340: 469-475. (Pubitemid 43021772)
33. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. (2002). A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2: 8.
34. Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T et al. (1999). beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 82: 625-629. (Pubitemid 29356957)
35. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A et al. (2007). Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/B-catanin and PI3K/Pten signaling pathways. Cancer Cell 11: 321-333. (Pubitemid 46518315)
36. Wu R, Zhai Y, Fearon ER, Cho KR. (2001). Diverse Mechanisms of beta-Catenin Deregulation in Ovarian Endometrioid Adenocarci-nomas. Cancer Res 61: 8247-8255. (Pubitemid 33091619)
37. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL et al. (2007). Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res 67: 10163-10172. (Pubitemid 350070788)
38. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT et al. (2002). Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 160: 1229-1238. (Pubitemid 34411627)